Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 6/17/2025 | $94.00 | Hold → Buy | Needham |
| 5/30/2025 | $76.00 | Overweight → Neutral | Analyst |
| 8/29/2024 | $115.00 → $120.00 | Overweight | Piper Sandler |
| 7/16/2024 | $107.00 → $115.00 | Hold → Buy | Jefferies |
| 3/19/2024 | $125.00 | Neutral → Buy | Redburn Atlantic |
| 3/13/2024 | $100.00 → $120.00 | Neutral → Overweight | JP Morgan |
| 2/6/2024 | Sector Weight | KeyBanc Capital Markets | |
| 10/30/2023 | $380.00 | Buy | BofA Securities |
Needham upgraded Cooper from Hold to Buy and set a new price target of $94.00
Analyst downgraded Cooper from Overweight to Neutral and set a new price target of $76.00
Piper Sandler reiterated coverage of Cooper with a rating of Overweight and set a new price target of $120.00 from $115.00 previously
SAN RAMON, Calif., April 30, 2025 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO), a leading global medical device company, announced today that its Board of Directors has appointed Barbara Carbone as an independent director, effective May 1, 2025. Ms. Carbone has also been appointed to serve on the Audit Committee when she joins the Board. Ms. Carbone brings nearly four decades of experience across a wide variety of industries. She spent most of her career at KPMG LLP, from 1981-2019, where she served more than twenty-four years as an Audit Partner. She served on the KPMG Partnership Audit Committee for six years, including three years as the Chairperson, and as the National Partner in
Evolus, Inc. (NASDAQ:EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today announced the appointment of Albert G. White III, President and Chief Executive Officer of The Cooper Companies, Inc. to the Evolus Board of Directors, effective July 1. Mr. White will also serve as a member of Evolus' Compensation Committee. "We are pleased to welcome Al White to the Evolus Board," said Vik Malik, Chairman of the Board of Directors. "Al's extensive leadership experience, industry knowledge, and proven track record of building a leading medical technology company will be a valuable resource as Evolus embarks on a path from a single-product aes
SAN RAMON, Calif., Nov. 30, 2023 (GLOBE NEWSWIRE) -- CooperCompanies (NASDAQ:COO) announced today that its Board of Directors has appointed Lawrence E. Kurzius as an independent director, effective December 1, 2023. Kurzius has also been appointed to serve on the Audit Committee and Organization & Compensation Committee when he joins the Board. "We are thrilled to welcome Lawrence to our Board of Directors," said Al White, President and CEO. "His track record of successfully leading a complex, multinational organization will be extremely valuable to CooperCompanies as we continue to drive global growth at CooperVision and CooperSurgical." Kurzius served as Chief Executive Officer of McCo